Global Strategic Business Outlook on the Testosterone Replacement Therapy (TRT) Market 2015-2018 to 2022 - Easy-to-use Formulations is a Major Boost to the Market - ResearchAndMarkets.com

July 4, 2018

DUBLIN--(BUSINESS WIRE)--Jul 4, 2018--The “Testosterone Replacement Therapy (TRT) - Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. The report analyzes the worldwide markets in US$ Million.

The global and US markets are further analyzed by the following Product Segments:

Topicals Patches Others

The report profiles 29 companies including many key and niche players such as:

AbbVie, Inc. (USA) Acerus Pharmaceuticals Corporation (Canada) Acrux Limited (Australia) Antares Pharma, Inc. (USA) Bayer HealthCare Pharmaceuticals (Germany) Eli Lilly and Company (USA) Endo Pharmaceuticals Inc. (USA) Kyowa Kirin (UK)

Key Topics Covered

1. Industry Overview

2. Growth Drivers and Market Trends

Aging Global Population Drives Adoption Undiagnosed Patients - A Strong Indicator of Growth Potential Rising Awareness - A Critical Factor for Growth Untapped Developing Markets - The Future Growth Engine for TRT Emerging Data on Positive Impact on Co-morbidities to Support Growth Debunking Conventional Wisdom, New Studies Dissociate Prostate Cancer Risk with TRT Marketing Campaigns and Patient Referrals to Fuel Growth Easy-to-use Formulations - A Major Boost to TRT Market Testosterone as Treatment for Other Conditions - A Growing Area of Focus

3. Competition

4. Testosterone Deficiency and TRT

5. Product Launches/Approvals

6. Recent Industry Activity

7. Focus on Select Players

8. Global Market Perspective

Total Companies Profiled: 29 (including Divisions/Subsidiaries 31)

The United States (17) Canada (2) Japan (2) Europe (7) Germany (1)The United Kingdom (4)Rest of Europe (2) Asia-Pacific (Excluding Japan) (3)

For more information about this report visit https://www.researchandmarkets.com/research/6vvlwq/global_strategic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180704005193/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/04/2018 10:09 AM/DISC: 07/04/2018 10:09 AM


Update hourly